Merck & Co., Inc. (MRK) Stock Forecast & Price Target

$128.97 +1.20 (+0.94%)

As of 01:21 PM Eastern

Compare

Merck & Co., Inc. - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 20 Analyst Ratings

Sell
0

Hold
7

Buy
13

Based on 20 Wall Street analysts who have issued ratings for Merck & Co., Inc. in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 7 have given a hold rating, and 13 have given a buy rating for MRK.

Consensus Price Target

$134.50
4.29% Upside

According to the 20 analysts' twelve-month price targets for Merck & Co., Inc., the average price target is $134.50. The highest price target for MRK is $155.00, while the lowest price target for MRK is $90.00. The average price target represents a forecasted upside of 4.29% from the current price of $128.97.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for MRK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Merck & Co., Inc. and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MRK Analyst Ratings Over Time

Type	Current Forecast 8/4/25 to 8/4/26	1 Month Ago 7/5/25 to 7/5/26	3 Months Ago 5/6/25 to 5/6/26	1 Year Ago 8/4/24 to 8/4/25
Strong Buy	0 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	12 Buy rating(s)	11 Buy rating(s)	6 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)	11 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$134.50	$131.83	$128.18	$107.44
Forecasted Upside	4.29% Upside	1.93% Upside	12.90% Upside	34.42% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

MRK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MRK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Merck & Co., Inc. Stock vs. The Competition

Type	Merck & Co., Inc.	Healthcare Companies	Broader Market
Consensus Rating Score	2.65	2.31	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	5.31% Upside	926.60% Upside	12.62% Upside
News Sentiment Rating	Positive News See Recent MRK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
7/29/2026	Barclays 3 of 5 stars	Emily Field Not Rated	Boost Target	Overweight	$140.00 ➝ $150.00	+13.77%
7/13/2026	JPMorgan Chase & Co. 3 of 5 stars	Chris Schott 5 of 5 stars	Boost Target	Overweight	$135.00 ➝ $140.00	+13.12%
7/13/2026	BMO Capital Markets 3 of 5 stars	Evan David Seigerman 3 of 5 stars	Boost Target	Outperform	$135.00 ➝ $142.00	+14.78%
7/13/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vamil Divan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$140.00 ➝ $145.00	+17.20%
7/9/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terence Flynn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$112.00 ➝ $113.00	-9.54%
7/8/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Trung Huynh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$142.00	+12.53%
7/8/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$145.00 ➝ $150.00	+16.40%
7/6/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Carter Gould Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral	$120.00	-7.22%
6/30/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tim Anderson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$130.00 ➝ $141.00	+9.87%
6/30/2026	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Louise Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sector Outperform	$136.00 ➝ $155.00	+22.02%
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown” (Ad) In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets. See Jim Rickards' full market warning and what it means for your portfolio
6/24/2026	CICC Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform	$138.00	+14.65%
5/15/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Hold (C+) ➝ Hold (C)
5/6/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Neutral	$125.00	+9.91%
4/13/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Yee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$130.00 ➝ $145.00	+20.64%
3/17/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong Sell ➝ Hold
2/13/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Shin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$150.00	+25.78%
1/20/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steve Scala Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$100.00 ➝ $120.00	+10.33%
1/8/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alexandria Hammond Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$135.00	+24.40%
12/2/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terence Flynn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$92.00 ➝ $120.00	+19.12%
9/17/2025	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luisa Hector Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$100.00 ➝ $90.00	+11.02%
2/10/2025	TD Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold	$121.00 ➝ $100.00	+15.45%
1/13/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daina Graybosch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$136.00 ➝ $119.00	+19.31%
1/8/2025	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold	$130.00 ➝ $110.00	+8.88%
12/4/2024	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy	$130.00	+27.65%
11/11/2024	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Neutral
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Courtney Breen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Market Perform	$115.00	+4.14%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:21 PM ET.

Should I Buy Merck & Co., Inc. Stock? MRK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, July 29, 2026. Please send any questions or comments about these Merck & Co., Inc. pros and cons to contact@marketbeat.com.

Merck & Co., Inc.
Bull Case

Here are some ways that investors could benefit from investing in Merck:

Merck has a strong return on equity, indicating effective management and profitability, which can attract investors looking for solid financial performance.
The company recently announced a quarterly dividend of $0.85, translating to an annualized dividend yield of approximately 2.6%, providing a steady income stream for shareholders.
Merck's revenue for the latest quarter was significantly above analyst expectations, showcasing its robust market position and potential for growth.
Recent developments in Merck's investigational HIV medication, alimatravir, highlight the company's commitment to expanding its product portfolio and addressing global health challenges, which could lead to increased market share if approved.
The current stock price is around $100, making it an attractive entry point for investors looking to capitalize on potential future growth.

Merck & Co., Inc.
Bear Case

Investors should be bearish about investing in Merck for these reasons:

The company's high dividend payout ratio of 95.77% suggests that a large portion of earnings is being distributed to shareholders, which may limit funds available for reinvestment in growth opportunities.
Merck faces competitive pressure from generic versions of its established products, such as the recent launch of a generic version of Janumet XR, which could negatively impact sales and market share.
Despite positive revenue growth, the overall net margin of 13.59% indicates that there may be challenges in maintaining profitability amidst rising costs or competitive pricing pressures.
Market speculation around Merck's stock, particularly related to its HIV pipeline, may lead to volatility, which could deter risk-averse investors.
Analysts forecast a modest earnings per share of 2.74 for the current year, which may not meet the expectations of growth-oriented investors looking for higher returns.

MRK Forecast - Frequently Asked Questions

According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Merck & Co., Inc. is $134.50, with a high forecast of $155.00 and a low forecast of $90.00.

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 7 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MRK shares.

According to analysts, Merck & Co., Inc.'s stock has a predicted upside of 4.29% based on their 12-month stock forecasts.

Over the previous 90 days, Merck & Co., Inc.'s stock had 1 downgrade by analysts.

Merck & Co., Inc. has been rated by research analysts at Bank of America, Barclays, BMO Capital Markets, Cantor Fitzgerald, CICC Research, Citigroup, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, Royal Bank Of Canada, Scotiabank, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Merck & Co., Inc. more than other "healthcare" companies. The consensus rating for Merck & Co., Inc. is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how MRK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Merck & Co., Inc. Recommendations

This page (NYSE:MRK) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Merck & Co., Inc. (MRK) Stock Forecast & Price Target

Merck & Co., Inc. - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

MRK Analyst Ratings Over Time

MRK Analyst Recommendations By Month

MRK Price Targets by Month

Merck & Co., Inc. Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Merck & Co., Inc. Stock? MRK Pros and Cons Explained

Merck & Co., Inc.
Bull Case

Merck & Co., Inc.
Bear Case

MRK Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Merck & Co., Inc. Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Merck & Co., Inc. (MRK) Stock Forecast & Price Target

Merck & Co., Inc. - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

MRK Analyst Ratings Over Time

MRK Analyst Recommendations By Month

MRK Price Targets by Month

Merck & Co., Inc. Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Merck & Co., Inc. Stock? MRK Pros and Cons Explained

Merck & Co., Inc. Bull Case

Merck & Co., Inc. Bear Case

MRK Forecast - Frequently Asked Questions

What is Merck & Co., Inc.'s forecast for 2026?

Should I buy or sell Merck & Co., Inc. stock right now?

Does Merck & Co., Inc.'s stock price have much upside?

Has Merck & Co., Inc. been downgraded by Wall Street analysts recently?

What analysts cover Merck & Co., Inc.?

Do Wall Street analysts like Merck & Co., Inc. more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Merck & Co., Inc. Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Merck & Co., Inc.
Bull Case

Merck & Co., Inc.
Bear Case